Galectin Therapeutics Inc
GALT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001133416
In the last 90 days, Galectin Therapeutics Inc insiders filed 0 open-market purchases and 1 sale; 98 institutions reported holding it in 13F filings for Q2 2026, worth $72.2M in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding Galectin Therapeutics Inc changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 60 | 60 | 0 |
| Shares | 7.17M | 7.28M | +107.3K (+1.5%) |
| Value | $15.0M | $10.5M | −$4.56M (−30.3%) |
New holders (3)
Institutions that held Galectin Therapeutics Inc at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Summit Trail Advisors, LLC | 20,000 | $28.8K | 0.00% |
| Connor, Clark & Lunn Investment Management Ltd. | 15,933 | $22.9K | 0.00% |
| Clearstead Advisors, LLC | 1,500 | $2.16K | 0.00% |
Sold out (3)
Institutions that held Galectin Therapeutics Inc at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Jane Street Group, LLC | 40,522 | $85.1K |
| FMR LLC | 3,200 | $6.72K |
| Belpointe Asset Management LLC | 1,066 | $2.24K |